# Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

> **NCT01625156** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Adult Solid Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Temsirolimus
- **DRUG:** Tivantinib

## Key facts

- **NCT ID:** NCT01625156
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-09
- **Final completion:** 2015-10
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625156, "Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01625156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*